{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:25:12Z","timestamp":1782368712371,"version":"3.54.5"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Keloids and hypertrophic scars are conditions of pathologic scarring characterized by fibroblast hyperproliferation and excess collagen deposition. These conditions significantly impact patients by causing psychosocial, functional, and aesthetic distress. Current treatment modalities have limitations. Clinical evidence indicates that botulinum toxin A (BoNT-A) may prevent and treat keloids and hypertrophic scars.<\/jats:p><\/jats:sec><jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>To examine investigated cellular pathways involved in BoNT-A therapeutic modulation of keloids and hypertrophic scars.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors searched PubMed, Embase, and Web of Science for basic science articles related to botulinum toxin therapy, scarring, fibroblasts, keloids, and hypertrophic scars.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Eleven basic science articles involving keloids and hypertrophic scars were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>DISCUSSION<\/jats:title><jats:p>BoNT-A may reduce skin fibrosis by decreasing fibroblast proliferation, modulating the activity of transforming growth factor-\u03b2, and reducing transcription and expression of profibrotic cytokines in keloid-derived and hypertrophic scar\u2013derived dermal fibroblasts. BoNT-A may modulate collagen deposition, but there is a paucity of evidence regarding specific mechanisms of action.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Overall, BoNT-A has the potential to prevent or treat pathologic scars in patients with a known personal or family history of keloids and hypertrophic scars, which may improve patient psychosocial distress and reduce clinic visits and health care costs. Variability in keloid and hypertrophic scar response to BoNT-A may be due to interexperiment differences in dosing, tissue donors, and assay sensitivity.<\/jats:p><\/jats:sec>","DOI":"10.1097\/dss.0000000000001360","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T21:12:54Z","timestamp":1512853974000},"page":"149-157","source":"Crossref","is-referenced-by-count":49,"title":["The Cellular Response of Keloids and Hypertrophic Scars to Botulinum Toxin A: A Comprehensive Literature Review"],"prefix":"10.1097","volume":"44","author":[{"given":"Evan","family":"Austin","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California at Davis, Sacramento, California;"},{"name":"Dermatology Service, Sacramento VA Medical Center, Mather, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Koo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California at Davis, Sacramento, California;"},{"name":"Dermatology Service, Sacramento VA Medical Center, Mather, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Jagdeo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California at Davis, Sacramento, California;"},{"name":"Dermatology Service, Sacramento VA Medical Center, Mather, California;"},{"name":"Department of Dermatology, State University of New York, Downstate Medical Center, Brooklyn, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00403-009-1014-y","article-title":"Genetics of keloid scarring","volume":"302","author":"Shih","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1046\/j.1365-2133.1999.03047.x","article-title":"A study of the spectrum of skin disease occurring in a black population in south-east London","volume":"141","author":"Child","year":"1999","journal-title":"Br J Dermatol"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjd.13826","article-title":"Epidemiology of keloids in normally pigmented Africans and African people with albinism: population-based cross-sectional survey","volume":"173","author":"Kiprono","year":"2015","journal-title":"Br J Dermatol"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2119\/molmed.2009.00153","article-title":"Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies","volume":"17","author":"Gauglitz","year":"2011","journal-title":"Mol Med"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00403-014-1491-5","article-title":"Keloid incidence in Asian people and its comorbidity with other fibrosis-related diseases: a nationwide population-based study","volume":"306","author":"Sun","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1468-3083.2006.02036.x","article-title":"Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey","volume":"21","author":"Yang","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0929-6646(08)60004-2","article-title":"Prevalence of skin diseases among schoolchildren in Magong, Penghu, Taiwan: a community-based clinical survey","volume":"107","author":"Chen","year":"2008","journal-title":"J Formos Med Assoc"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-4362.1992.tb02718.x","article-title":"Incidence of skin disease in Cuzco","volume":"31","author":"Failmezger","year":"1992","journal-title":"Peru Int J Dermatol"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.burns.2005.01.022","article-title":"Prevalence of hypertrophic scar formation and its characteristics among the Chinese population","volume":"31","author":"Li-Tsang","year":"2005","journal-title":"Burns"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0305-4179(03)00067-6","article-title":"What is the prevalence of hypertrophic scarring following burns?","volume":"29","author":"Bombaro","year":"2003","journal-title":"Burns"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/01.prs.0000472474.17120.84","article-title":"Emotional quality of life is severely affected by keloid disease: pain and itch are the main determinants of burden","volume":"136","author":"Kouwenberg","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bjps.2008.03.020","article-title":"The hidden cost of skin scars: quality of life after skin scarring","volume":"61","author":"Brown","year":"2008","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R13-20230814","first-page":"688","article-title":"DLQI scores in patients with keloids and hypertrophic scars: a prospective case control study [in German]","volume":"7","author":"Balci","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.burns.2014.02.011","article-title":"Up-to-date approach to manage keloids and hypertrophic scars: a useful guide","volume":"40","author":"Arno","year":"2014","journal-title":"Burns"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/PRS.0b013e3181c82dd5","article-title":"The most current algorithms for the treatment and prevention of hypertrophic scars and keloids","volume":"125","author":"Ogawa","year":"2010","journal-title":"Plast Reconstr Surg"},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/jocd.12134","article-title":"Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial","volume":"14","author":"Shaarawy","year":"2015","journal-title":"J Cosmet Dermatol"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/229255031302100208","article-title":"Eradication of keloids: surgical excision followed by a single injection of intralesional 5-fluorouracil and botulinum toxin","volume":"21","author":"Wilson","year":"2013","journal-title":"Can J Plast Surg"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00266-009-9334-z","article-title":"Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report","volume":"33","author":"Xiao","year":"2009","journal-title":"Aesthet Plast Surg"},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/PHM.0b013e3181c1ec11","article-title":"Treatment of a painful keloid with botulinum toxin type A","volume":"89","author":"Uyesugi","year":"2010","journal-title":"Am J Phys Med Rehabil"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4103\/0378-6323.173586","article-title":"Assessment of intralesional injection of botulinum toxin type A injection for hypertrophic scars","volume":"82","author":"Elhefnawy","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.bjps.2012.08.042","article-title":"Keloid scars and treatment with botulinum toxin type a: the belfast experience","volume":"66","author":"Robinson","year":"2013","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R22-20230814","first-page":"14","article-title":"Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes","volume":"3","author":"Perdanasari","year":"2015","journal-title":"Burns Trauma"},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"e0151627","DOI":"10.1371\/journal.pone.0151627","article-title":"Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"R24-20230814","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/DSS.0000000000000278","article-title":"New frontiers and clinical applications for botulinum neuromodulators","volume":"41","author":"Jagdeo","year":"2015","journal-title":"Dermatol Surg"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tox.2015.07.003","article-title":"Botulinum neurotoxin type A: actions beyond SNAP-25?","volume":"335","author":"Matak","year":"2015","journal-title":"Toxicology"},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000342125","article-title":"Botulinum toxin A for the treatment of keloids","volume":"25","author":"Gauglitz","year":"2012","journal-title":"Skin Pharmacol Physiol"},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"114","DOI":"10.14730\/aaps.2013.19.2.114","article-title":"The effects of botulinum toxin a on collagen synthesis, expression of MMP (matrix metalloproteinases)-1,2,9 and TIMP (tissue inhibitors of metalloproteinase)-1 in the keloid fibroblasts","volume":"19","author":"Roh","year":"2013","journal-title":"Arch Aesthet Plast Surg"},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1090820X13482938","article-title":"Effects of botulinum toxin type A on expression of genes in keloid fibroblasts","volume":"34","author":"Wang","year":"2014","journal-title":"Aesthet Surg J"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/lary.24456","article-title":"Effects of botulinum toxin A on patient-specific keloid fibroblasts in vitro","volume":"124","author":"Haubner","year":"2014","journal-title":"Laryngoscope"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bjps.2008.05.003","article-title":"Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar","volume":"61","author":"Xiao","year":"2008","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00266-009-9423-z","article-title":"Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report","volume":"34","author":"Xiao","year":"2010","journal-title":"Aesthet Plast Surg"},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00266-011-9690-3","article-title":"Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar","volume":"35","author":"Xiao","year":"2011","journal-title":"Aesthet Plast Surg"},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"171e","DOI":"10.1097\/PRS.0000000000001438","article-title":"Effect of botulinum toxin type a on differentiation of fibroblasts derived from scar tissue","volume":"136","author":"Jeong","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3390\/molecules17022169","article-title":"Effects of botulinum toxin type a on collagen deposition in hypertrophic scars","volume":"17","author":"Xiao","year":"2012","journal-title":"Molecules"},{"key":"R36-20230814","first-page":"1603","article-title":"Intralesional treatments for hypertrophic scars: comparison among corticosteroid, 5-fluorouracil and botulinum toxin in rabbit ear hypertrophic scar model","volume":"20","author":"Caliskan","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00266-017-0803-5","article-title":"Effect of BTXA on inhibiting hypertrophic scar formation in a rabbit ear model","volume":"41","author":"Liu","year":"2017","journal-title":"Aesthet Plast Surg"},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archfaci.2011.734","article-title":"Effects of botulinum toxin a on cytokine synthesis in a cell culture model of cutaneous scarring","volume":"14","author":"Haubner","year":"2012","journal-title":"Arch Facial Plast Surg"},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1524-4725.2012.02504.x","article-title":"The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study","volume":"38","author":"Oh","year":"2012","journal-title":"Dermatol Surg"},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1097\/SAP.0000000000000268","article-title":"Botulinum toxin type a inhibits alpha-smooth muscle actin and myosin II expression in fibroblasts derived from scar contracture","volume":"77","author":"Chen","year":"2016","journal-title":"Ann Plast Surg"},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2133.2005.06698.x","article-title":"Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration","volume":"153","author":"Fujiwara","year":"2005","journal-title":"Br J Dermatol"},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cbf.1537","article-title":"Matrix metalloproteinase-2 and-9 activities in human keloids, hypertrophic and atrophic scars: a pilot study","volume":"27","author":"Tanriverdi-Akhisaroglu","year":"2009","journal-title":"Cell Biochem Funct"},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00403-013-1410-1","article-title":"The role of microRNAs in skin fibrosis","volume":"305","author":"Babalola","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1524-4725.2008.34406.x","article-title":"Hypertrophic scars and keloids\u2014a review of their pathophysiology, risk factors, and therapeutic management","volume":"35","author":"Wolfram","year":"2009","journal-title":"Dermatol Surg"},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/iwj.12228","article-title":"The effect of botulinum neurotoxin type A on capsule formation around silicone implants: the in vivo and in vitro study","volume":"13","author":"Lee","year":"2016","journal-title":"Int Wound J"},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"821e","DOI":"10.1097\/PRS.0000000000002625","article-title":"Effect of botulinum toxin type a on TGF-beta\/Smad pathway Signaling: implications for silicone-induced capsule formation","volume":"138","author":"Kim","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/01.mop.0000236389.41462.ef","article-title":"Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management","volume":"18","author":"Slemp","year":"2006","journal-title":"Curr Opin Pediatr"},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3892\/ijmm_00000231","article-title":"Keloids: current concepts of pathogenesis (review)","volume":"24","author":"Bran","year":"2009","journal-title":"Int J Mol Med"},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/BCR.0b013e31818ba189","article-title":"Animal models of keloids and hypertrophic scars","volume":"29","author":"Ogawa","year":"2008","journal-title":"J Burn Care Res"},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0765.2007.01022.x","article-title":"Substance P regulates the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in cultured human gingival fibroblasts","volume":"43","author":"Cury","year":"2008","journal-title":"J Periodontal Res"},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/019021499270303","article-title":"Migration of 3T3 and lung fibroblasts in response to calcitonin gene-related peptide and bombesin","volume":"25","author":"Yule","year":"1999","journal-title":"Exp Lung Res"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201802000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T13:08:46Z","timestamp":1751116126000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201802000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001360","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}